ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc (LIXT)

2.2795
-0.0305
(-1.32%)
Closed May 29 4:00PM
2.2795
0.00
(0.00%)
After Hours: 4:02PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.2795
Bid
2.20
Ask
2.50
Volume
7,819
2.25 Day's Range 2.3608
1.58 52 Week Range 9.50
Market Cap
Previous Close
2.31
Open
2.35
Last Trade
44
@
2.28
Last Trade Time
Financial Volume
$ 17,961
VWAP
2.2971
Average Volume (3m)
580,289
Shares Outstanding
2,249,290
Dividend Yield
-
PE Ratio
-1.01
Earnings Per Share (EPS)
-2.26
Revenue
-
Net Profit
-5.09M

About Lixte Biotechnology Holdings Inc

Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies ar... Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lixte Biotechnology Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LIXT. The last closing price for Lixte Biotechnology was $2.31. Over the last year, Lixte Biotechnology shares have traded in a share price range of $ 1.58 to $ 9.50.

Lixte Biotechnology currently has 2,249,290 shares outstanding. The market capitalization of Lixte Biotechnology is $5.13 million. Lixte Biotechnology has a price to earnings ratio (PE ratio) of -1.01.

LIXT Latest News

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston PASADENA, CA, May 08, 2024...

Mixed Shelf Filing Gives Micro Cap Delayed Boost

A California-based biotech company is finding pretty serious success on Wednesday a day after the company filed a registration statement covering the potential sale of up to $50 To read the full...

Biotech Steals The Show Following Pre-Clinical Data Announcement

A California-based biotech company stirred things up on Wednesday after it was announced the publication of preclinical data on its lead clinical compound, LB-100.

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE...

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or...

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology...

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2405-9.543650793652.522.56672.2527422.40708352CS
4-0.6105-21.1245674742.893.052.25106252.54742505CS
12-0.1805-7.337398373982.464.42.15675802893.50196308CS
26-0.7105-23.7625418062.994.41.692910343.41785573CS
52-4.4205-65.97761194036.79.51.581956733.8808987CS
156-25.1205-91.680656934327.449.51.5872048417.41947393CS
260-36.2205-94.079220779238.571.91.5871437821.7037428CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
BNAIBrand Engagement Network Inc
$ 2.6062
(105.21%)
108.22M
ONCOOnconetix Inc
$ 0.2949
(79.93%)
137.82M
ASTSAST SpaceMobile Inc
$ 9.0199
(69.23%)
109.9M
KTRAKintara Therapeutics Inc
$ 0.272
(44.76%)
81.59M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
AWINAERWINS Technologies Inc
$ 5.555
(-39.22%)
2.01M
HLTHCue Health Inc
$ 0.0553
(-38.96%)
72.11M
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
PLTNUPlutoniam Acquisition Corporation
$ 5.83
(-34.57%)
965
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
RSLSReShape Lifesciences Inc
$ 0.2847
(37.01%)
212.55M
AALAmerican Airlines Group Inc
$ 11.62
(-13.54%)
159.16M

LIXT Discussion

View Posts
Monksdream Monksdream 1 month ago
LIXT under $5
👍️0
bigfart bigfart 2 months ago
Another one hit wonder it moved on news
👍️0
Monksdream Monksdream 2 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Awl416 Awl416 2 months ago
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
👍️0
Awl416 Awl416 3 months ago
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
👍️0
81vette 81vette 7 months ago
Perfectly predictable chart,pullbacks to sma 100% so far
👍️0
81vette 81vette 7 months ago
No debt,current ratio $7.49
👍️0
81vette 81vette 7 months ago
Some $60k-$90k buys,institutional buys starting?12%currently,up2%
👍️0
81vette 81vette 7 months ago
-.02 accumulation Friday,now +.115,loading going on!!
👍️0
81vette 81vette 7 months ago
Not optionable,shares to short dropping
👍️0
81vette 81vette 7 months ago
1.73M float/s.o. 2.25M,12Xs buying vol
👍️0
Monksdream Monksdream 9 months ago
LIXT new 52 week low
👍️0
Monksdream Monksdream 10 months ago
July 17, 2023
8:30 am ET
Preclinical Results of LIXTE Biotechnology's Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Globe Newswire
👍️0
Mr Rollup Mr Rollup 1 year ago
Amazing to watch 1.64 to flat same day. SEC sleeps again
👍️0
glenn1919 glenn1919 1 year ago
LIXT......................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783
👍️0
TheFinalCD TheFinalCD 1 year ago
LIXT NEWS 1.50'S


MAYBE OFFERING NEXT


WE KNOW THEY NEED IT= $$$$$$$$$$$$$$$$$$$$
👍️0
Invest-in-America Invest-in-America 1 year ago
LIXT: Just more "HYPER-STIMULATION" of the PRICE of their stock!! (HA-HA!!!)
👍️0
TheFinalCD TheFinalCD 1 year ago
1.01 WAS LOD SUCH A SHAME
👍️0
IVANj IVANj 1 year ago
Still no offering… we bouncing here??
👍️0
TheFinalCD TheFinalCD 1 year ago
LIXT 1.34X1.36 could go again, if volume comes in and squeezes= $LIXT here is the technical chart with the inside bar on daily..... i buy the dip never the rip +100 or 200% works better pic.twitter.com/k6IlsHMUIy— Antonio Costa (@ACInvestorBlog) February 8, 2023
👍️0
TheFinalCD TheFinalCD 1 year ago
1.29 I think they want people to chase a pop before the company wakes up and announces an offer


thats what I think
👍️0
TheFinalCD TheFinalCD 1 year ago
LIXT trying 1.30 break after just dumped to 1.16 again


all these are PD's controlled by robots
👍️0
Invest-in-America Invest-in-America 1 year ago
LIXT: And gettin' even LOWER in the A.F. routine, Boss.

PS: But SOUN, BBAI, et al., all UP a bit behind that Bing Search Engine news & 'AI Voice' stuff.
👍️0
TheFinalCD TheFinalCD 1 year ago
yup 1.39
👍️0
Invest-in-America Invest-in-America 1 year ago
LIXT: Indeed, G-2-G!! Evidently, Peeps are getting --- as they should be --- rather JADED behind the obligatory, NEXT-GREAT-CANCER-CURE-OF-THE-DAY, routines!! And the subject one here, is nowhere near the HUMAN Phase studies level. And, their PR was FUNNY, to boot!!! E.g., stimulate, feed, promote, & otherwise AUGMENT the Cancer cells entire cellular STRUCTURES to such extreme extent, that they FORGET that they are indeed CANCER cells in the FIRST PLACE --- and then they will act NORMAL, & NOT want to metastasize anywhere!!!!! Where they KIDDING us all??????
👍️0
TheFinalCD TheFinalCD 1 year ago
LIXT 2.56 @ 3:30 NOW 1.50

PRETTY SICK...NO???

ITS NOT LIKE THERE WAS AN OFFERING FOR CHEAP SAKES
👍️0
Invest-in-America Invest-in-America 1 year ago
LIXT:
https://www.marketscreener.com/quote/stock/LIXTE-BIOTECHNOLOGY-HOLDI-302255/news/LIXTE-BIOTECHNOLOGY-HOLDINGS-INC-REPORTS-THAT-ITS-LEAD-CLINICAL-COMPOUND-LB-100-CAN-KILL-CANCER-42921763/
👍️0
europtiger europtiger 1 year ago
Thx for the heads up… got me 3k just below 2$ but stop is in
👍️0
tortiello tortiello 1 year ago
HUGE NEWS
👍️0
TheFinalCD TheFinalCD 1 year ago
https://finviz.com/quote.ashx?t=LIXT&ty=c&ta=1&p=d
👍️0
europtiger europtiger 2 years ago
I belive this will see a nice move near therm
👍️0
Investinyoface Investinyoface 2 years ago
Took a position $1.30

$LIXT
👍️0
europtiger europtiger 2 years ago
Loaded 1,18
👍️0
trendzone trendzone 2 years ago
Corrupted MM or short hedge fund criminals are engaged in all out corrupt manipulation in the after hours to steal shares, or use their tools of manipulation to cover shorts,this kind of criminal act by this trash needs to get burned.
👍️0
Pedro2004 Pedro2004 2 years ago
Good Morning.

I lost money on the last run. I got caught in a massive dump (like today).
I watched this a bit today, and it's the same trading pattern.
Looks like it's a combination of the company dumping shares, and heavy shorting.
👍️0
PStockPickz PStockPickz 2 years ago
Yep in . Thanks!
👍️0
hedge_fun hedge_fun 2 years ago
Being the savvy trader I am, I was waiting.......

to see if the $2.40 support level held.

I'm still waiting.......BWAHAHAHAHA

Congrats longs!
👍️0
Roadtojourney Roadtojourney 2 years ago
Now every company want to release similar news?? Imo
👍️0
TheFinalCD TheFinalCD 2 years ago
low ss https://finviz.com/quote.ashx?t=LIXT&ty=c&ta=1&p=d
👍️0
Man6677 Man6677 2 years ago
Thank you Buddy !

Very nice
👍️0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/lixte-biotechnology-LIXT/stock-news/87813772/lixte-biotechnology-announces-preclinical-results
👍️0
Man6677 Man6677 2 years ago
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Source: GlobeNewswire Inc.

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers, and Stichting Oncode Institute (Oncode Institute), Utrecht, a major independent cancer research center, has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergistic anti-cancer effects in cancer patients.
Lixte previously announced its entry into a collaboration with the NKI and Oncode Institute to identify the most promising drugs to be used in combination with Lixte’s LB-100 or with one of Lixte’s LB-100 analogues to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.

John S. Kovach, MD, the founder and CEO of Lixte, commented "The new findings support the hypothesis advanced by Professor Bernards at the NKI (Dias and Bernards, Mol Onc, 2021) that rather than the usual therapeutic approach to cancer – inhibiting overactive pathways that drive cancer growth – further stimulation of those pathways can overwhelm the cancer cells, rendering them exceptionally vulnerable to particular stress-targeted drugs, while sparing the normal cells. This ‘paradoxical intervention’ is truly groundbreaking and may be applicable to a broad range of cancers."

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, by demonstrating that this compound is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells damaged by chemotherapy or other cancer therapies to continue to replicate before repairing the damage, leading to more efficient killing of cancer cells. LB-100 is being tested in three clinical cancer treatment studies, with others in planning. www.lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533



LIXT $$$$
👍️0
Man6677 Man6677 2 years ago
Not much Shares traded until now , but it‘s going up and up

LIXT $$$$
👍️0
Man6677 Man6677 2 years ago
Nice job today here

LIXT $$$
👍️0
Man6677 Man6677 2 years ago
Good Volume is coming in here !

LIXT $$$$
👍️0
Man6677 Man6677 2 years ago
Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Source: GlobeNewswire Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of colorectal, triple-negative breast, and pancreatic cancer. The authors state that “these data indicate that PP2A inhibition can be used to change the intrinsic and extrinsic factors of tumors to improve the success rate of anti-cancer immunotherapy.”
Lixte’s founder and CEO, John S. Kovach M.D, commented that “recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers. Unfortunately, most cancer patients do not respond to immunotherapy. There are widespread efforts to find pharmacologic and/or immunologic ways to turn unresponsive (‘cold’) tumors into responsive (‘hot’) tumors. Cancers with a molecular abnormality termed microsatellite-instability (MSI) stemming from a defect in a DNA repair enzyme are generally ‘hot’ tumors, that is, tumors responsive to immunotherapy. Yen and colleagues now report that pharmacologic inhibition of PP2A by LB-100 modifies two distinct molecular pathways resulting in conversion of microsatellite stable (MSS) tumors into MSI tumors sensitive immune checkpoint blockade therapy.”

Dr. Kovach concluded: “The results of Yen et al. raise the possibility that the addition of LB-100 to immunotherapy may be a simple way to convert ‘cold’ into ‘hot’ tumors, thereby increasing the percentage of patients responsive to immunotherapy. Lixte recently initiated a clinical trial in patients with previously untreated extensive stage small cell lung cancer in which LB-100 is first added to chemotherapy and an immune checkpoint blocker and then administered with the immune blocker alone in the maintenance phase of treatment (NCT04560972). Lixte is interested in collaborative studies designed to determine whether LB-100 broadly enhances the benefit of immunotherapy. Immune checkpoint blockers are now approved for treatment of at least 20 cancer types.”

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, by demonstrating that this compound is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells damaged by chemo or other cancer therapies to continue to replicate before repairing the damage, leading to more efficient killing of those cells. LB-100 is being tested in three clinical cancer treatment studies with others in planning. www.lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533

LIXT $$$$
👍️0
Roadtojourney Roadtojourney 2 years ago
Same as today, seems like they have history of pnd imo??
👍️0
Man6677 Man6677 2 years ago
For a pump and dump it‘s holding well !
👍️0
Pedro2004 Pedro2004 2 years ago
Another pump-and-dump PR today.
👍️0
Pedro2004 Pedro2004 2 years ago
Wow. This company likes to rip-off shareholders.
👍️0

Your Recent History

Delayed Upgrade Clock